Panel Discussion of Challenging Patient Cases in HIV

Led by Kathleen E. Squires, MD, a panel of experts discusses their approach to management and prevention of HIV infection in complex clinical scenarios.
Joseph J. Eron, Jr., MD
Monica Gandhi, MD, MPH
W. David Hardy, MD
Kathleen E. Squires, MD
Physicians: maximum of 1.25 AMA PRA Category 1 Credits
Registered Nurses: 1.1 Nursing contact hours
Pharmacists: 1.25 contact hours (0.13 CEUs)
Released: May 1, 2017 Expiration: April 30, 2018

Learning Objectives

Upon completion of this activity, participants should be able to:
  • Apply the results of recent clinical studies on ARTs, including newer agents, in initial therapy and in switch strategies for HIV-infected patients
  • Effectively prevent or manage adverse events and other complications associated with HIV, ART, and comorbidities
  • Apply evidence-based strategies for the use of ART as prevention

Information on this Educational Activity

Disclosure of Conflicts of Interest

The Annenberg Center assesses conflict of interest with its instructors, planners, managers, and other individuals who are in a position to control the content of CME activities. All relevant conflicts of interest that are identified are thoroughly vetted by the Annenberg Center for fair balance, scientific objectivity of studies utilized in this activity, and patient care recommendations. The Annenberg Center is committed to providing its learners with high-quality CME activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.

The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:

Faculty

Joseph J. Eron, Jr., MD

Professor of Medicine and Epidemiology
University of North Carolina School of Medicine
Director, AIDS Clinical Trials Unit
University of North Carolina
Chapel Hill, North Carolina

Joseph J. Eron, Jr., MD, has disclosed that he has received consulting fees from Bristol‐Myers Squibb, Gilead Sciences, Janssen, Merck, and ViiV and funds for research support from AbbVie, Bristol‐Myers Squibb, Gilead Sciences, Janssen, and ViiV.
Monica Gandhi, MD, MPH

Professor of Medicine
Division of HIV, Infectious Diseases, and Global Medicine
University of California, San Francisco
Medical Director
Ward 86 HIV Clinic
San Francisco General Hospital
San Francisco, California

Monica Gandhi, MD, MPH, has no real or apparent conflicts of interest to report.
W. David Hardy, MD

Adjunct Professor of Medicine
Division of Infectious Diseases
Johns Hopkins University School of Medicine
Baltimore, Maryland
Senior Director of Evidence-Based Practices
Whitman-Walker Health
Washington, DC

W. David Hardy, MD, has disclosed that he has received consulting fees from Gilead Sciences, Janssen, Theratechnologies, and ViiV and funds for research support from Amgen, Bristol-Myers Squibb, CytoDyn, Gilead Sciences, Janssen, Merck, and ViiV.
Kathleen E. Squires, MD

W. Paul and Ida H. Havens Professor of Infectious Diseases
Director,
Division of Infectious Diseases
Sidney Kimmel Medical College of Thomas Jefferson University
Philadelphia, Pennsylvania

Kathleen E. Squires, MD, has disclosed that she has received funds for research support from Gilead Sciences and has served on advisory boards for Bristol‐Myers Squibb, Gilead Sciences, Janssen, Merck, and ViiV.

Staff

Megan Cartwright, PhD

Clinical Editor

Megan Cartwright, PhD, has no real or apparent conflicts of interest to report.
Jenny Schulz, PhD

Editorial Director, Virology & Other Therapeutic Areas

Jenny Schulz, PhD, has no real or apparent conflicts of interest to report.
Zachary Schwartz, MSc, ELS

Managing Editor

Zachary Schwartz, MSc, ELS, has no real or apparent conflicts of interest to report.

Additional Faculty
Eric S. Daar, MD, has disclosed that he has received funds for research support from Gilead Sciences, Merck, and ViiV and has served on advisory boards for Bristol‐Myers Squibb, Gilead Sciences, Merck, Janssen, Teva, and ViiV.

The planners and managers reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:

The following planners and managers, Trace Hutchison, PharmD, Samantha Mattiucci, PharmD, CHCP, Judi Smelker-Mitchek, RN, BSN and Jan Schultz, RN, MSN, CHCP, hereby state that they or their spouse/life partner do not have any financial relationships or relationships to products or devices with any commercial interest related to the content of this activity of any amount during the past 12 months.

Charles E. Willis, MBA, Director of Continuing Education, Amanda Sewell, MBA, Manager of Continuing Education, Debbie Price, Registration Database Administrator, and Alma Perez, Accreditation Specialist from the Annenberg Center for Health Sciences at Eisenhower have no relevant commercial relationships to disclose.

Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The Annenberg Center, Postgraduate Institute for Medicine (PIM), Clinical Care Options, and activity supporters do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the Annenberg Center, PIM, Clinical Care Options, and activity supporters. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Target Audience

This program is intended for HIV specialists, infectious diseases clinicians, registered nurses, pharmacists, and other healthcare professionals involved in the care of patients with HIV infection.

Goal

The goal of this activity is to improve participants’ competence in addressing the most important and most current challenges in HIV management by providing a tightly focused update on recent advances and key clinical issues encountered in the clinic.

Physician Continuing Medical Education

Accreditation Statement

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the Annenberg Center for Health Sciences at Eisenhower and Clinical Care Options, LLC. The Annenberg Center for Health Sciences at Eisenhower is accredited by the ACCME to provide continuing medical education for physicians.

Credit Designation

The Annenberg Center for Health Sciences at Eisenhower designates this enduring material for a maximum of 1.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nursing Continuing Education

Accreditation Statement

Annenberg Center for Health Sciences is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center's Commission on Accreditation..

Credit Designation

1.1 contact hours may be earned for successful completion of this activity.

Pharmacist Continuing Education

Accreditation Statement

The Annenberg Center for Health Sciences at Eisenhower is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.

Credit Designation

This program has been developed according to the ACPE Criteria for Quality and is assigned ACPE Universal Activity 0797-9999-17-037-H04-P. This program is designated for up to 1.25 contact hours (0.125 CEUs) of continuing pharmacy education credit.

Type of Activity Application

Program Medium

This program has been made available online.

Instructions for Credit

Participation in this self-study activity should be completed in approximately 1.25 hours. To successfully complete this activity and receive credit, participants must follow these steps during the period from May 01, 2017, through April 30, 2018:

1. Register online at http://www.clinicaloptions.com.
2. Read the target audience, learning objectives, and faculty disclosures.
3. Study the educational activity online or printed out.
4. Submit answers to the posttest questions and evaluation questions online.

You must receive a test score of at least 65% and respond to all evaluation questions to receive a certificate. After submitting the evaluation, you may access your online certificate by selecting the certificate link on the posttest confirmation page. Records of all CME activities completed can be found on the "CME Manager" page. There are no costs/fees for this activity.

Related Content

Watch an HIV expert panel discuss managing HCV infection in MSM, prescribing HIV PrEP to a PWID, and managing CVD in an HIV-infected woman.

W. David Hardy, MD
Program Director
Princy N. Kumar, MD person default Jaimie P. Meyer, MD, MS, FACP Babafemi Taiwo, MBBS
Physicians: maximum of 1.0 AMA PRA Category 1 Credit Registered Nurses: 1.0 Nursing contact hour Pharmacists: 1.0 contact hour (0.1 CEUs) Released: June 18, 2018 Expiration: June 17, 2019

CME-certified expert panel discussion on initiating or switching ART in a series of challenging patient cases.

Monica Gandhi, MD, MPH
Program Director
Eric S. Daar, MD Sally Hodder, MD Babafemi Taiwo, MBBS
Physicians: maximum of 1.25 AMA PRA Category 1 Credits Registered Nurses: 1.2 Nursing contact hours Pharmacists: 1.25 contact hours (0.13 CEUs) Released: June 15, 2018 Expiration: June 14, 2019

Eric S. Daar, MD
Program Director
Joseph J. Eron, Jr., MD
Program Director
Daniel R. Kuritzkes, MD
Program Director
José R. Arribas, MD
Released: June 13, 2018

Full slides: controversies in PrEP, ART initiation, and HIV treatment choices. From David A. Wohl, MD, Joseph J. Eron, Jr., MD, Princy N. Kumar, MD.

Joseph J. Eron, Jr., MD
Program Director
Princy N. Kumar, MD
Program Director
David A. Wohl, MD
Released: May 29, 2018

Acknowledgements

Jointly provided by Annenberg Center for Health Sciences at Eisenhower and Clinical Care Options, LLC
ACHS Logo

Annenberg Center for Health Sciences at Eisenhower
39000 Bob Hope Dr
Dinah Shore Bldg.
Rancho Mirage, CA 92270

Alma Perez, Accreditation Specialist
(760) 773-4506
(760) 773-4550 (Fax)
ce@annenberg.net
http://www.annenberg.net/

Educational grant provided by:
AbbVie
Bristol-Myers Squibb
Gilead Sciences
Janssen Therapeutics
Merck & Co., Inc.
ViiV Healthcare

Welcome to the CCO site.

You are accessing CCO's educational content today as a Guest user.

If you would like to continue with free, full access to the CCO Web sites, including free CME/CE credits, please click the button below.

Continue

More info

CCO’s educational programs are available completely free of charge on the ClinicalOptions.com, inPractice.com, and inPracticeAfrica.com Web sites. Certain features and functions are restricted for Guest users. By consenting to become a full member, you are eligible to receive CME/CE credit or participation certificates from certified activities, to register for CCO’s free live meetings and webinars, and to receive CCO’s email newsletters alerting you to new content. You can unsubscribe from our emails at any time. CCO strictly protects the privacy of our members, according to our privacy policy.

A confirmation email will be sent to . Not You?